RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- Quintiles
Transnational Corp. today announced the appointment of Christopher H.
Cabell, M.D., MHS, FACC, as Chief Medical and Scientific Officer. Cabell
succeeds Oren Cohen, M.D., who was recently appointed Senior Vice
President, Clinical Research Strategies.
As Chief Medical and Scientific Officer, Cabell will be responsible for
company-wide initiatives that focus on bioethics and the protection of
human subjects. In addition, he will be responsible for developing
initiatives that bring forward innovations in medicine, science and
technology into future business models.
Most recently, Cabell held the position of Global Cardiovascular /
Endocrine Therapeutic Group Leader within the Medical and Scientific
Services group and provided cardiology expertise for Quintiles
Electrocardiogram (ECG) Services. In 2007, Cabell joined Quintiles from the
Duke University School of Medicine, where he developed a strong background
in clinical research. He held several appointments within the Duke Clinical
Research Institute (DCRI), including Co-Chair and Principal Investigator
for a Duke/FDA Cardiac Safety partnership to develop a new generation of
tools to identify the potential effects of medical devices and drugs on the
heart. Also within DCRI, he held appointments as Director of the
Echocardiography Core Laboratory, Associate Director of the ECG Core
Laboratory and Director of the International Collaboration on Endocarditis.
He also was Assistant Professor of Medicine in the Division of Cardiology.
Cabell has authored or co-authored 50 articles for peer-reviewed
publications and delivered more than 30 invited lectures. He is a member of
several professional organizations, a Fellow of the American College of
Cardiology, and a reviewer for a number of medical journals, including the
Journal of the American Medical Association. He earned his medical degree
and a Master's in Health Science from the Duke University School of
Medicine.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, commercialization and strategic partnering for the
pharmaceutical, biotechnology and medical device industries. With more than
21,000 employees and offices in more than 50 countries, it is focused on
providing customer-centric solutions that are the gold standard of the
industry. For more information, please visit the company's Web site at
http://www.qtrn.com
SOURCE Quintiles Transnational Corp.
 back to top
Related links:
http://www.qtrn.com
CONTACT:
Mari Mansfield of Quintiles Transnational
Corp., Media Relations, +1-919-998-2639 (office), +1-919-259-3298
(mobile), mari.mansfield@quintiles.com
|
